MAAT PHARMA SACA (MAAT.PA) Stock Analyst Ratings
Europe - Euronext Paris - EPA:MAAT - FR0012634822 - Common Stock
4.79 EUR
+0.03 (+0.63%)
ChartMill assigns a Buy % Consensus number of 88% to MAAT.PA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 17.12. This target is 257.44% above the current price.
MAAT.PA was analyzed by 13 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about MAAT.PA.
In the previous month the buy percentage consensus was at a similar level.
MAAT.PA was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-04-07 | STIFEL EUROPE | Maintains | Buy -> Buy |
MAAT PHARMA SACA / MAAT.PA FAQ
What is the average price target for MAAT PHARMA SACA (MAAT.PA) stock?
13 analysts have analysed MAAT.PA and the average price target is 17.12 EUR. This implies a price increase of 257.44% is expected in the next year compared to the current price of 4.79.
How do analysts rate MAAT PHARMA SACA (MAAT.PA)?
The consensus rating for MAAT PHARMA SACA (MAAT.PA) is 87.6923 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed MAAT PHARMA SACA (MAAT.PA)?
The number of analysts covering MAAT PHARMA SACA (MAAT.PA) is 13.